Chris Molloy on investment in dementia; AI in healthcare; TechBio; BioJapan; bioProcessUK; Green, Conservative and Labour conferences; and BIA Board elections
Chris Molloy on the Labour Party conference; female biotech leaders in Edinburgh; Women in Biotech mentoring programme; Advanced Therapy Treatment Centre; BioSolutions Advisory Board; TechBio UK; and careers at BIA
£135 million for two life sciences funds, rare disease R&D, Beacon Therapeutics, Basecamp Research’s Series C, Birmingham Life Sciences Week, Liberal Democrat party conference, Women in Biotech Edinburgh
Causeway Sensors and Fusion Antibodies share a case study on how TITAN’s real-time, at-line analytics detected key harvest yield differences by Day 3, enabling early process intervention and smarter resource allocation.
Chris Molloy on mRNA cancer vaccine reaching Phase 3 milestone, Scancell MHRA authorisation, microbiome-based medicinal products, MHRA voucher scheme for SMEs, Scotland and data driver projects
Claire Smith, who sits on BIA’s Intellectual Property Advisory Committee (IPAC) committee, and James Johnston explain what the US BIOSECURE Act means for UK biotech companies
Chris Molloy on Mike Hoare, the RedX-Skye deal, Stablepharma’s fridge-free vaccine, MHRA quarterly numbers, ministerial responsibilities for UK life sciences and human biology-based models
